Enzymotec (ENZY) Announces Investigator-Initiated Trial of Vayarin in ADHD
Tweet Send to a Friend
Enzymotec (Nasdaq: ENZY) announced that Dr. Sylvain Rheims, Head of the Department of Functional Neurology and Epileptology at Hospices Civils ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
